AVITA Medical Sees Q1 Commercial Revenue $14.8M-$15.6M, Sees FY24 Commercial Revenue $79.5M-$84.5M
Portfolio Pulse from Benzinga Newsdesk
AVITA Medical anticipates Q1 commercial revenue to be between $14.8M and $15.6M, and forecasts FY24 commercial revenue to range from $79.5M to $84.5M.
January 10, 2024 | 2:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AVITA Medical, trading as RCEL, expects Q1 commercial revenue between $14.8M-$15.6M and FY24 revenue between $79.5M-$84.5M.
The positive revenue guidance provided by AVITA Medical for both Q1 and FY24 suggests a strong performance and potential growth, which is likely to be viewed favorably by investors. This could lead to a short-term increase in the stock price of RCEL, reflecting investor optimism about the company's financial outlook.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100